Arovella Therapeutics Limited (ALA.AX)
AUD 0.08
(0.0%)
AUD 0.08
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 | 10.78 Million AUD | 61.44% |
| 2023 | 6.68 Million AUD | -13.07% |
| 2022 | 7.68 Million AUD | 63.49% |
| 2021 | 4.7 Million AUD | -8.47% |
| 2020 | 5.13 Million AUD | 51.04% |
| 2019 | 3.4 Million AUD | -46.43% |
| 2018 | 6.34 Million AUD | 73.34% |
| 2017 | 3.66 Million AUD | -2.23% |
| 2016 | 3.74 Million AUD | -20.68% |
| 2015 | 4.72 Million AUD | -0.04% |
| 2014 | 4.72 Million AUD | 82.81% |
| 2013 | 2.58 Million AUD | 1.06% |
| 2012 | 2.55 Million AUD | -25.99% |
| 2011 | 3.45 Million AUD | 63.18% |
| 2010 | 2.11 Million AUD | -16.1% |
| 2009 | 2.52 Million AUD | -62.78% |
| 2008 | 6.77 Million AUD | 19.37% |
| 2007 | 5.67 Million AUD | 22.08% |
| 2006 | 4.65 Million AUD | 6.6% |
| 2005 | 4.36 Million AUD | 195.5% |
| 2004 | 1.47 Million AUD | 37.32% |
| 2003 | 1.07 Million AUD | 689.82% |
| 2002 | 136.15 Thousand AUD | 57.32% |
| 2001 | 86.55 Thousand AUD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 4.49 Million AUD | 50.65% |
| 2024 Q3 | 2.01 Million AUD | -55.1% |
| 2024 FY | 10.78 Million AUD | 61.44% |
| 2024 Q4 | 2.01 Million AUD | 0.0% |
| 2024 Q1 | 2.98 Million AUD | -9.17% |
| 2023 Q3 | 3.16 Million AUD | -4.1% |
| 2023 Q2 | 3.3 Million AUD | 28.87% |
| 2023 Q1 | 2.56 Million AUD | -5.37% |
| 2023 FY | 6.68 Million AUD | -13.07% |
| 2023 Q4 | 3.28 Million AUD | 3.73% |
| 2022 Q3 | 2.41 Million AUD | 18.51% |
| 2022 Q4 | 2.7 Million AUD | 12.02% |
| 2022 FY | 7.68 Million AUD | 63.49% |
| 2022 Q1 | 1.84 Million AUD | 11.29% |
| 2022 Q2 | 2.03 Million AUD | 10.71% |
| 2021 Q2 | 1.1 Million AUD | 13.1% |
| 2021 Q3 | 1.9 Million AUD | 71.92% |
| 2021 Q4 | 1.65 Million AUD | -13.17% |
| 2021 FY | 4.7 Million AUD | -8.47% |
| 2021 Q1 | 980.38 Thousand AUD | -42.42% |
| 2020 FY | 5.13 Million AUD | 51.04% |
| 2020 Q2 | 1.44 Million AUD | -63.58% |
| 2020 Q1 | 3.97 Million AUD | 326.32% |
| 2020 Q3 | 1.51 Million AUD | 4.73% |
| 2020 Q4 | 1.7 Million AUD | 12.27% |
| 2019 Q3 | 4.02 Million AUD | 404.64% |
| 2019 Q2 | 798.14 Thousand AUD | 0.0% |
| 2019 Q1 | 798.14 Thousand AUD | -63.39% |
| 2019 Q4 | 932.55 Thousand AUD | -76.85% |
| 2019 FY | 3.4 Million AUD | -46.43% |
| 2018 Q4 | 2.18 Million AUD | -3.12% |
| 2018 Q2 | 1.2 Million AUD | 0.0% |
| 2018 FY | 6.34 Million AUD | 73.34% |
| 2018 Q1 | 1.2 Million AUD | 376.71% |
| 2018 Q3 | 2.25 Million AUD | 87.21% |
| 2017 Q4 | 252.14 Thousand AUD | -69.36% |
| 2017 FY | 3.66 Million AUD | -2.23% |
| 2017 Q3 | 823.01 Thousand AUD | 19.91% |
| 2017 Q2 | 686.38 Thousand AUD | 0.0% |
| 2017 Q1 | 686.38 Thousand AUD | -4.14% |
| 2016 Q1 | 1.15 Million AUD | 4.5% |
| 2016 FY | 3.74 Million AUD | -20.68% |
| 2016 Q4 | 716.05 Thousand AUD | 0.0% |
| 2016 Q2 | 1.15 Million AUD | -0.0% |
| 2016 Q3 | 716.05 Thousand AUD | -38.07% |
| 2015 FY | 4.72 Million AUD | -0.04% |
| 2015 Q4 | 1.1 Million AUD | 0.0% |
| 2015 Q3 | 1.1 Million AUD | -11.58% |
| 2015 Q2 | 1.25 Million AUD | 0.0% |
| 2015 Q1 | 1.25 Million AUD | 3.49% |
| 2014 Q2 | 1.15 Million AUD | -0.0% |
| 2014 Q1 | 1.15 Million AUD | 81.0% |
| 2014 FY | 4.72 Million AUD | 82.81% |
| 2014 Q4 | 1.2 Million AUD | 0.0% |
| 2014 Q3 | 1.2 Million AUD | 4.94% |
| 2013 Q1 | 653.06 Thousand AUD | 0.0% |
| 2013 Q3 | 636.65 Thousand AUD | -2.51% |
| 2013 Q4 | 636.65 Thousand AUD | 0.0% |
| 2013 FY | 2.58 Million AUD | 1.06% |
| 2013 Q2 | 653.06 Thousand AUD | 0.0% |
| 2012 FY | 2.55 Million AUD | -25.99% |
| 2011 FY | 3.45 Million AUD | 63.18% |
| 2010 FY | 2.11 Million AUD | -16.1% |
| 2009 FY | 2.52 Million AUD | -62.78% |
| 2008 FY | 6.77 Million AUD | 19.37% |
| 2007 FY | 5.67 Million AUD | 22.08% |
| 2006 FY | 4.65 Million AUD | 6.6% |
| 2005 FY | 4.36 Million AUD | 195.5% |
| 2004 FY | 1.47 Million AUD | 37.32% |
| 2003 FY | 1.07 Million AUD | 689.82% |
| 2002 FY | 136.15 Thousand AUD | 57.32% |
| 2001 FY | 86.55 Thousand AUD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| AdAlta Limited | 6.76 Million AUD | -59.322% |
| Acrux Limited | 8.55 Million AUD | -26.144% |
| Actinogen Medical Limited | 22.77 Million AUD | 52.635% |
| AnteoTech Limited | 12.18 Million AUD | 11.502% |
| Argenica Therapeutics Limited | 8.26 Million AUD | -30.428% |
| Anatara Lifesciences Ltd | 710.21 Thousand AUD | -1418.59% |
| Alterity Therapeutics Limited | 23.4 Million AUD | 53.922% |
| Amplia Therapeutics Limited | 8.43 Million AUD | -27.852% |
| Avecho Biotechnology Limited | 4.54 Million AUD | -137.279% |
| Bio-Gene Technology Limited | 2.76 Million AUD | -290.628% |
| Biome Australia Limited | 7.91 Million AUD | -36.329% |
| Biotron Limited | 5.11 Million AUD | -111.034% |
| Botanix Pharmaceuticals Limited | 601.82 Thousand AUD | -1692.111% |
| BTC Health Limited | -1.03 Million AUD | 1138.117% |
| Chimeric Therapeutics Limited | 19.76 Million AUD | 45.439% |
| CSL Limited | 7.56 Billion AUD | 99.857% |
| Clarity Pharmaceuticals Ltd | 56.3 Million AUD | 80.846% |
| Clinuvel Pharmaceuticals Limited | 31.29 Million AUD | 65.539% |
| Cynata Therapeutics Limited | 11.12 Million AUD | 3.041% |
| Dimerix Limited | 25.64 Million AUD | 57.941% |
| EZZ Life Science Holdings Limited | 39.57 Million AUD | 72.747% |
| Hexima Limited | 1 Million AUD | -969.173% |
| Island Pharmaceuticals Limited | 4.12 Million AUD | -161.439% |
| Immuron Limited | 9.13 Million AUD | -18.028% |
| Immutep Limited | 42.87 Million AUD | 74.845% |
| Imugene Limited | 135.09 Million AUD | 92.016% |
| Invex Therapeutics Ltd | 3.34 Million AUD | -222.345% |
| Memphasys Limited | 3.67 Million AUD | -193.207% |
| Nanollose Limited | 12.5 Thousand AUD | -86175.354% |
| Neuren Pharmaceuticals Limited | 32.69 Million AUD | 67.014% |
| Noxopharm Limited | 7 Million AUD | -54.071% |
| NeuroScientific Biopharmaceuticals Limited | 1.96 Million AUD | -448.808% |
| Nyrada Inc. | 4.55 Million AUD | -136.77% |
| Orthocell Limited | 15.36 Million AUD | 29.827% |
| PharmAust Limited | 6.65 Million AUD | -62.014% |
| Patrys Limited | 4.93 Million AUD | -118.621% |
| Paradigm Biopharmaceuticals Limited | 65.1 Million AUD | 83.434% |
| Proteomics International Laboratories Limited | 892.14 Thousand AUD | -1108.919% |
| Prescient Therapeutics Limited | 10.89 Million AUD | 1.041% |
| PYC Therapeutics Limited | 60.91 Million AUD | 82.295% |
| Race Oncology Limited | 14.77 Million AUD | 26.981% |
| Radiopharm Theranostics Limited | 299.22 Thousand AUD | -3504.369% |
| Recce Pharmaceuticals Ltd | 21.68 Million AUD | 50.263% |
| Starpharma Holdings Limited | 22.81 Million AUD | 52.729% |
| Telix Pharmaceuticals Limited | 269.26 Million AUD | 95.995% |
| Tissue Repair Ltd | 6.66 Million AUD | -61.776% |
| Zelira Therapeutics Limited | 5.94 Million AUD | -81.311% |